RT Journal Article
SR Electronic
T1 Chemosensory dysfunctions induced by COVID-19 can persist up to 7 months: A study of over 700 healthcare workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21259639
DO 10.1101/2021.06.28.21259639
A1 Nicholas Bussière
A1 Jie Mei
A1 Cindy Lévesque-Boissonneault
A1 Mathieu Blais
A1 Sara Carazo
A1 Francois Gros-Louis
A1 Gaston De Serres
A1 Nicolas Dupré
A1 Johannes Frasnelli
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.06.28.21259639.abstract
AB Several studies have revealed either self-reported chemosensory alterations in large groups or objective quantified chemosensory impairments in smaller populations of patients diagnosed with COVID-19. However, due to the great variability in published results regarding COVID-19-induced chemosensory impairments and their follow-up, prognosis for chemosensory functions in patients with such complaints remains unclear. Our objective is to describe the various chemosensory alterations associated with COVID-19 and their prevalence and evolution after infection. A cross-sectional study of 704 healthcare workers with a RT-PCR confirmed SARS-CoV-2 infection between 28/2/2020 and 14/6/2020 was conducted 3 to 7 months after onset of symptoms. Data were collected with an online questionnaire. Outcomes included differences in reported chemosensory self-assessment of olfactory, gustatory, and trigeminal functions across time points and Chemosensory Perception Test scores from an easy-to-use at-home self-administered chemosensory test. Among the 704 participants, 593 (84.2%) were women, the mean (SD) age was 42 (12) years, and the questionnaire was answered on average 4.8 (0.8) months after COVID-19. During COVID-19, a decrease in olfactory, gustatory, and trigeminal sensitivities were reported by 81.3%, 81.5% and 48.0% respectively. Three to seven months later, reduced sensitivity was still reported by 52.0%, 41.9% and 23.3% respectively. Chemosensory Perception Test scores indicate that 19.5% of participants had objective olfactory impairment. These data suggest a significant proportion of COVID-19 cases have persistent chemosensory impairments at 3 to 7 months after their infection but the majority of those who had completely lost their olfactory, gustatory, and trigeminal sensitivity have improved.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported financially by Fonds de recherche du Quebec - Sante (chercheur boursier junior 2 #283144 to JF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the research ethics board of the CHU de Quebec - Universite Laval (MP-20-2021-5228) and all protocols were reviewed by an independent Scientific Review Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request.